AU2008335718A1 - Impaired wound healing compositions and treatments - Google Patents

Impaired wound healing compositions and treatments Download PDF

Info

Publication number
AU2008335718A1
AU2008335718A1 AU2008335718A AU2008335718A AU2008335718A1 AU 2008335718 A1 AU2008335718 A1 AU 2008335718A1 AU 2008335718 A AU2008335718 A AU 2008335718A AU 2008335718 A AU2008335718 A AU 2008335718A AU 2008335718 A1 AU2008335718 A1 AU 2008335718A1
Authority
AU
Australia
Prior art keywords
val
pro
artificial sequence
phe
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008335718A
Other languages
English (en)
Inventor
Bradford J. Duft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of AU2008335718A1 publication Critical patent/AU2008335718A1/en
Priority to AU2015200904A priority Critical patent/AU2015200904A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008335718A 2007-12-11 2008-12-11 Impaired wound healing compositions and treatments Abandoned AU2008335718A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015200904A AU2015200904A1 (en) 2007-12-11 2015-02-23 Impaired wound healing compositions and treatments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US726207P 2007-12-11 2007-12-11
US61/007,262 2007-12-11
PCT/US2008/013656 WO2009075882A2 (en) 2007-12-11 2008-12-11 Impaired wound healing compositions and treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200904A Division AU2015200904A1 (en) 2007-12-11 2015-02-23 Impaired wound healing compositions and treatments

Publications (1)

Publication Number Publication Date
AU2008335718A1 true AU2008335718A1 (en) 2009-06-18

Family

ID=40626592

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2008335718A Abandoned AU2008335718A1 (en) 2007-12-11 2008-12-11 Impaired wound healing compositions and treatments
AU2015200904A Abandoned AU2015200904A1 (en) 2007-12-11 2015-02-23 Impaired wound healing compositions and treatments

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015200904A Abandoned AU2015200904A1 (en) 2007-12-11 2015-02-23 Impaired wound healing compositions and treatments

Country Status (8)

Country Link
US (1) US20100279921A1 (enExample)
EP (1) EP2245158A2 (enExample)
JP (3) JP2011506447A (enExample)
CN (2) CN102920996A (enExample)
AU (2) AU2008335718A1 (enExample)
CA (1) CA2709153A1 (enExample)
WO (1) WO2009075882A2 (enExample)
ZA (1) ZA201004998B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9035037B2 (en) 2007-12-21 2015-05-19 Coda Therapeutics, Inc. Medical devices

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006257283A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
CA2672220A1 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110245184A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of surgical adhesions
WO2009085271A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
WO2009085275A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
JP2011507857A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の処置のためのコネキシン４３の阻害剤の使用
CA2710232A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
CA2710227A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of surgical adhesions
JP6185937B2 (ja) 2012-03-01 2017-08-23 ファーストストリング・リサーチ・インコーポレイテッドＦｉｒｓｔｓｔｒｉｎｇ Ｒｅｓｅａｒｃｈ，Ｉｎｃ． アルファコネキシンｃ末端（ａｃｔ）ペプチド含有局所用ゲル剤
US20140031753A1 (en) * 2012-07-25 2014-01-30 Neil T. Winthrop Thoracostomy devices and methods of use
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2940648A1 (en) * 2014-02-25 2015-09-03 Coda Therapeutics, Inc. Treatment of resistant lesions
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
CN109513037B (zh) * 2018-11-14 2021-09-17 华中科技大学同济医学院附属协和医院 一种负载介孔生物玻璃的小肠粘膜下层创面敷料
WO2021119198A1 (en) * 2019-12-09 2021-06-17 Cage Bio, Inc. Topical delivery of rna interference agents using ionic liquid
CN111214694B (zh) * 2020-03-31 2022-04-22 山东大鱼生物技术有限公司 一种具有止血和加速伤口愈合功能的敷料及其制备方法
CN116710474A (zh) 2020-10-22 2023-09-05 撒凯尔生物公司 肽制剂及其眼科用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (enExample) * 1988-08-05 1993-10-07
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
ATE533515T1 (de) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulierungen enthaltend antisense nukleotide spezifisch für connexine
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
JP2005516054A (ja) * 2002-01-29 2005-06-02 ワイス コネキシンヘミチャンネルを調節する組成物及びその方法
EP1827480B1 (en) * 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
AU2006257283A1 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
RU2542471C2 (ru) * 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
CA2672220A1 (en) * 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CA2709151A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009085271A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
CA2710388A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars
US20110245184A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of surgical adhesions
WO2009085275A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
CA2711635A1 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9035037B2 (en) 2007-12-21 2015-05-19 Coda Therapeutics, Inc. Medical devices
US9561311B2 (en) 2007-12-21 2017-02-07 Coda Therapeutics, Inc. Medical devices
US10251929B2 (en) 2007-12-21 2019-04-09 Ocunexus Theraprutics, Inc. Medical devices

Also Published As

Publication number Publication date
EP2245158A2 (en) 2010-11-03
WO2009075882A3 (en) 2009-07-30
JP2016135799A (ja) 2016-07-28
CN102920996A (zh) 2013-02-13
CN101970663A (zh) 2011-02-09
AU2015200904A1 (en) 2015-03-12
US20100279921A1 (en) 2010-11-04
JP2014144976A (ja) 2014-08-14
ZA201004998B (en) 2011-06-29
CA2709153A1 (en) 2009-06-18
WO2009075882A9 (en) 2009-09-17
WO2009075882A2 (en) 2009-06-18
JP2011506447A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
US20100279921A1 (en) Impaired wound healing compositions and treatments
AU2018200326B2 (en) Improved methods and compositions for wound healing
US9637745B2 (en) Impaired wound healing compositions and treatments
US20110038920A1 (en) Wound healing compositions and treatments
US20130184220A1 (en) Treatment of abnormal or excessive scars
US20180028468A1 (en) Sustained release drug delivery devices
AU2014204482B2 (en) Anticonnexin polynucleotides as impaired wound healing compositions
HK1136213B (en) Anticonnexin polynucleotides as impaired wound healing compositions

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted